Kymera Therapeutics Inc
kymeratx.comKymera Therapeutics (NASDAQ: KYMR) is a clinical-stage biopharmaceutical company focused on developing oral small molecule medicines using targeted protein degradation (TPD), a therapeutic modality that engages the body's natural cellular recycling system to selectively eliminate disease-causing proteins. The company has no approved products and generates revenue through collaboration agreements rather than product sales. Kymera's pipeline is centered on immunology, with lead programs targeting STAT6 (KT-621, in Phase 2b trials for atopic dermatitis and asthma), IRF5 (KT-579, in Phase 1 as of the 10-K filed 2026-02-26), and IRAK4 (KT-485/SAR447971, in collaboration with Sanofi S.A.). A strategic collaboration with Gilead Sciences, Inc. for CDK2 molecular glue degraders was announced in June 2025. Kymera was founded with a disease-agnostic drug discovery approach and aims to become a fully integrated biopharmaceutical company. The company relies on third parties to conduct clinical trials and has no commercial operations as of the filing date.
Products & Services
KT-621 (STAT6 degrader, Phase 2b in atopic dermatitis and asthma); KT-579 (IRF5 degrader, Phase 1 in healthy volunteers); KT-485/SAR447971 (IRAK4 degrader, partnered with Sanofi, planned clinical entry 2026); CDK2 molecular glue degrader program (partnered with Gilead Sciences, announced June 2025); additional undisclosed early-stage pipeline programs.
Revenue Model
Collaboration agreements with pharmaceutical partners, including Sanofi S.A. and Gilead Sciences, Inc. No product revenue as of the 10-K filed 2026-02-26. The company is pre-commercial and funds operations through partnership payments and capital raises.
Customers & Markets
Pharmaceutical collaboration partners (Sanofi S.A., Gilead Sciences, Inc.). End markets include immunology indications such as atopic dermatitis and asthma, with additional research in other therapeutic areas.
Financial Snapshot
Loading...
